Percutaneous Right Ventricular Support via ProtekDuo Pulmonary Artery Cannulation

ProtekDuo dual-lumen cannula implantation provides effective percutaneous right ventricular support in acute right heart failure. This retrospective study analyzed 60 patients who received ProtekDuo support for a mean of 14.9 ± 9.7 days. Hemodynamic improvements included reduced central venous pressure (17.8 ± 5.6–11.8 ± 5.0 mmHg, p < 0.001) and increased central venous oxygen saturation (60.6 ± 15.2–74.6% ± 7.8%, p < 0.001). End-organ function improved, with lower creatinine (2.9 ± 5.0–1.6 ± 0.8 mg/dl, p = 0.046) and lactate levels (26.0 ± 23.3–14.1 ± 10.4 mg/dl, p < 0.001). Bilirubin levels increased post-implantation (2.9 ± 3.2 to 5.7 ± 6.0 mg/dl, p < 0.001) but returned to baseline within 13.5 ± 19 days in weaned patients. Independent mortality risk factors were female sex (hazard ratio [HR] = 6.47, p < 0.001), older age (HR = 1.035, p = 0.036), and higher body mass index (BMI) (HR = 1.124, p = 0.003). These findings highlight the benefits of percutaneous ProtekDuo implantation in acute right heart failure, although patient selection remains critical. Further studies are needed to refine selection criteria and optimize outcomes.